Empagliflozin improves glycemia, blood pressure in type 2 diabetes study
Treatment with empagliflozin, an investigational sodium-glucose cotransporter 2 (SGLT2) inhibitor, was associated with benefits for blood pressure as well as glycemic control in a 3-month study of...